Vilma Maldonado

Dr. Vilma Maldonado

National Institute of Genomic Medicine, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2015 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
KVKARLA VAZQUEZ-SANTILLAN
KARLA VAZQUEZ-SANTILLAN
JMJ. Melendez-Zajgla
J. Melendez-Zajgla
LJL. Jimenez-Hernandez
L. Jimenez-Hernandez
GMG. Martínez-Ruiz
G. Martínez-Ruiz
VMVilma Maldonado
Vilma Maldonado

1 May 2017 in Archives of Medical Research
Verified
Journal Article
Closed access
CGCarolina Gonzalez-Torres
Carolina Gonzalez-Torres
JGJavier Gaytan-Cervantes
Javier Gaytan-Cervantes
KVKARLA VAZQUEZ-SANTILLAN
KARLA VAZQUEZ-SANTILLAN
EMEdna Ayerim Mandujano-Tinoco
Edna Ayerim Mandujano-Tinoco
GCGisela Ceballos-Cancino
Gisela Ceballos-Cancino
VMVilma Maldonado
Vilma Maldonado

9 June 2018 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
EMEdna Ayerim Mandujano-Tinoco
Edna Ayerim Mandujano-Tinoco
AGAlfredo García-Venzor
Alfredo García-Venzor
JMJorge Melendez-Zajgla
Jorge Melendez-Zajgla
VMVilma Maldonado
Vilma Maldonado

Verified
Journal Article
Open access
PDF file
AOAlejandro Ordaz-Ramos
Alejandro Ordaz-Ramos
VRVictor Hugo Rosales-Gallegos
Victor Hugo Rosales-Gallegos
JMJorge Melendez-Zajgla
Jorge Melendez-Zajgla
VMVilma Maldonado
Vilma Maldonado
KVKARLA VAZQUEZ-SANTILLAN
KARLA VAZQUEZ-SANTILLAN
Leucine-rich repeats containing G protein-coupled receptor 4 (LGR4) is a receptor that belongs to the superfamily of G protein-coupled receptors that can be activated by R-spondins (RSPOs), Norrin, circLGR4, and the ligand of the receptor activator of nuclear factor kappa-B (RANKL) ligands to regulate signaling pathways in normal and pathological processes. LGR4 is widely expressed in different tissues where it has multiple functions such as tissue development and maintenance. LGR4 mainly acts through the Wnt/β-catenin pathway to regulate proliferation, survival, and differentiation. In cancer, LGR4 participates in tumor progression, invasion, and metastasis. Furthermore, recent evidence reveals that LGR4 is essential for the regulation of the cancer stem cell population by controlling self-renewal and regulating stem cell properties. This review summarizes the function of LGR4 and its ligands in normal and malignant processes.

1 December 2019 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
AGAlfredo García-Venzor
Alfredo García-Venzor
EMEdna Ayerim Mandujano-Tinoco
Edna Ayerim Mandujano-Tinoco
FLFloria Lizarraga
Floria Lizarraga
CZCecilia Zampedri
Cecilia Zampedri
EKEdgar Krötzsch
Edgar Krötzsch
VMVilma Maldonado
Vilma Maldonado

25 December 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
IAIrma Beatriz Mitre Aguilar
Irma Beatriz Mitre Aguilar
DMDaniel Moreno-Mitre
Daniel Moreno-Mitre
JMJorge Melendez-Zajgla
Jorge Melendez-Zajgla
VMVilma Maldonado
Vilma Maldonado
NJNadia Jacobo-Herrera
Nadia Jacobo-Herrera
GMGretel Mendoza
Gretel Mendoza
Glucocorticoids (GCs) are anti-inflammatory and immunosuppressive steroid molecules secreted by the adrenal gland and regulated by the hypothalamic–pituitary–adrenal (HPA) axis. GCs present a circadian release pattern under normal conditions; they increase their release under stress conditions. Their mechanism of action can be via the receptor-independent or receptor-dependent pathway. The receptor-dependent pathway translocates to the nucleus, where the ligand-receptor complex binds to specific sequences in the DNA to modulate the transcription of specific genes. The glucocorticoid receptor (GR) and its endogenous ligand cortisol (CORT) in humans, and corticosterone in rodents or its exogenous ligand, dexamethasone (DEX), have been extensively studied in breast cancer. Its clinical utility in oncology has mainly focused on using DEX as an antiemetic to prevent chemotherapy-induced nausea and vomiting. In this review, we compile the results reported in the literature in recent years, highlighting current trends and unresolved controversies in this field. Specifically, in breast cancer, GR is considered a marker of poor prognosis, and a therapeutic target for the triple-negative breast cancer (TNBC) subtype, and efforts are being made to develop better GR antagonists with fewer side effects. It is necessary to know the type of breast cancer to differentiate the treatment for estrogen receptor (ER)-positive, ER-negative, and TNBC, to implement therapies that include the use of GCs.